JP2023531390A5 - - Google Patents
Info
- Publication number
- JP2023531390A5 JP2023531390A5 JP2022576009A JP2022576009A JP2023531390A5 JP 2023531390 A5 JP2023531390 A5 JP 2023531390A5 JP 2022576009 A JP2022576009 A JP 2022576009A JP 2022576009 A JP2022576009 A JP 2022576009A JP 2023531390 A5 JP2023531390 A5 JP 2023531390A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- acceptable salt
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025277389A JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010536221.6 | 2020-06-12 | ||
| CN202010536221 | 2020-06-12 | ||
| CN202011147078.8 | 2020-10-23 | ||
| CN202011147078 | 2020-10-23 | ||
| CN202011261665.X | 2020-11-12 | ||
| CN202011261665 | 2020-11-12 | ||
| CN202110485680 | 2021-04-30 | ||
| CN202110485680.0 | 2021-04-30 | ||
| CN202110614030.1 | 2021-06-02 | ||
| CN202110614030 | 2021-06-02 | ||
| PCT/CN2021/099654 WO2021249534A1 (zh) | 2020-06-12 | 2021-06-11 | 酞嗪酮类化合物及其制备方法和医药用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025277389A Division JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531390A JP2023531390A (ja) | 2023-07-24 |
| JP2023531390A5 true JP2023531390A5 (https=) | 2024-06-19 |
| JP7797421B2 JP7797421B2 (ja) | 2026-01-13 |
Family
ID=78846889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576009A Active JP7797421B2 (ja) | 2020-06-12 | 2021-06-11 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
| JP2025277389A Pending JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025277389A Pending JP2026053536A (ja) | 2020-06-12 | 2025-12-23 | フタラジノン化合物、並びにその調製方法及びその医薬用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20230131252A1 (https=) |
| EP (1) | EP4166550A4 (https=) |
| JP (2) | JP7797421B2 (https=) |
| KR (1) | KR20230024328A (https=) |
| CN (2) | CN113801098B (https=) |
| AU (1) | AU2021286738A1 (https=) |
| BR (1) | BR112022025057A2 (https=) |
| CA (1) | CA3186981A1 (https=) |
| CL (1) | CL2022003472A1 (https=) |
| CO (1) | CO2022017802A2 (https=) |
| CR (1) | CR20230007A (https=) |
| IL (1) | IL298962A (https=) |
| MX (1) | MX2022015562A (https=) |
| PE (1) | PE20230610A1 (https=) |
| PH (1) | PH12023550018A1 (https=) |
| SA (1) | SA522441725B1 (https=) |
| TW (1) | TWI781651B (https=) |
| WO (1) | WO2021249534A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN114829342A (zh) | 2019-12-23 | 2022-07-29 | 上海济煜医药科技有限公司 | 一种蛋白降解剂化合物的制备方法和应用 |
| JP2023520916A (ja) * | 2020-04-08 | 2023-05-22 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| CR20230007A (es) * | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| JP2024519628A (ja) * | 2021-05-26 | 2024-05-21 | イノキュア セラピューティクス インコーポレイテッド | ピペリジンジオン誘導体 |
| KR102474999B1 (ko) * | 2021-05-26 | 2022-12-07 | 주식회사 이노큐어테라퓨틱스 | 피페리딘디온 유도체 |
| TW202321219A (zh) | 2021-08-11 | 2023-06-01 | 大陸商四川海思科製藥有限公司 | 雜環衍生物及其組合物和藥學上的應用 |
| WO2024054953A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2024054952A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| EP4624472A1 (en) * | 2022-11-22 | 2025-10-01 | Innocure Therapeutics, Inc. | Degrader including novel c-met protein ligand and pharmaceutical composition including same |
| KR20240076746A (ko) * | 2022-11-22 | 2024-05-30 | 주식회사 이노큐어테라퓨틱스 | Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물 |
| KR20240075764A (ko) * | 2022-11-22 | 2024-05-29 | 주식회사 이노큐어테라퓨틱스 | cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물 |
| CN116655591B (zh) * | 2023-06-05 | 2024-11-08 | 中国人民解放军军事科学院军事医学研究院 | 3,4-二氢酞嗪-1（2h）-酮类衍生物及制备方法和用途 |
| CN121773112A (zh) | 2023-08-17 | 2026-03-31 | 海思科医药集团股份有限公司 | 一种氰基芳香环衍生物及其在医药上的应用 |
| WO2025062330A1 (en) | 2023-09-20 | 2025-03-27 | Aurigene Oncology Limited | Heterocyclic compounds as cbp selective degraders |
| CN120025333A (zh) * | 2023-11-22 | 2025-05-23 | 广东东阳光药业股份有限公司 | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025193849A1 (en) | 2024-03-13 | 2025-09-18 | Genentech, Inc. | Polymorphs of ar-degraders |
| WO2025193851A1 (en) | 2024-03-13 | 2025-09-18 | Genentech, Inc. | Process for making enantiomers of ar-degraders |
| WO2025226797A1 (en) | 2024-04-24 | 2025-10-30 | Genentech, Inc. | Kred catalyzed ketoreduction of a cyclobutanone carbamic ester |
| US12169941B1 (en) | 2024-06-13 | 2024-12-17 | Rapsodo Pte. Ltd. | System and method for determining a position an object crosses a target plane |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| CA3042297A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN110194762B (zh) * | 2018-02-27 | 2021-09-10 | 中国科学院上海药物研究所 | 酞嗪酮类衍生物、其制备方法和用途 |
| CN112390852B (zh) | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| CN112457367B (zh) | 2019-09-06 | 2022-08-23 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的连环类化合物及其制备方法和应用 |
| CN112457366B (zh) | 2019-09-06 | 2024-03-19 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和应用 |
| CN118930604A (zh) | 2019-09-29 | 2024-11-12 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用 |
| CN114829342A (zh) | 2019-12-23 | 2022-07-29 | 上海济煜医药科技有限公司 | 一种蛋白降解剂化合物的制备方法和应用 |
| CN113582974B (zh) | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
| CR20230007A (es) * | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
-
2021
- 2021-06-11 CR CR20230007A patent/CR20230007A/es unknown
- 2021-06-11 IL IL298962A patent/IL298962A/en unknown
- 2021-06-11 PE PE2022002889A patent/PE20230610A1/es unknown
- 2021-06-11 JP JP2022576009A patent/JP7797421B2/ja active Active
- 2021-06-11 MX MX2022015562A patent/MX2022015562A/es unknown
- 2021-06-11 CN CN202110653817.9A patent/CN113801098B/zh active Active
- 2021-06-11 WO PCT/CN2021/099654 patent/WO2021249534A1/zh not_active Ceased
- 2021-06-11 AU AU2021286738A patent/AU2021286738A1/en active Pending
- 2021-06-11 CA CA3186981A patent/CA3186981A1/en active Pending
- 2021-06-11 EP EP21822688.4A patent/EP4166550A4/en active Pending
- 2021-06-11 PH PH1/2023/550018A patent/PH12023550018A1/en unknown
- 2021-06-11 CN CN202310167758.3A patent/CN116082311B/zh active Active
- 2021-06-11 KR KR1020237000214A patent/KR20230024328A/ko active Pending
- 2021-06-11 BR BR112022025057A patent/BR112022025057A2/pt unknown
- 2021-06-11 TW TW110121476A patent/TWI781651B/zh active
-
2022
- 2022-12-07 CO CONC2022/0017802A patent/CO2022017802A2/es unknown
- 2022-12-07 CL CL2022003472A patent/CL2022003472A1/es unknown
- 2022-12-12 SA SA522441725A patent/SA522441725B1/ar unknown
- 2022-12-12 US US18/079,778 patent/US20230131252A1/en active Pending
-
2023
- 2023-04-05 US US18/131,309 patent/US11767312B2/en active Active
-
2024
- 2024-08-14 US US18/804,443 patent/US12234223B2/en active Active
-
2025
- 2025-12-23 JP JP2025277389A patent/JP2026053536A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531390A5 (https=) | ||
| JP2023508097A5 (https=) | ||
| FI4129989T3 (fi) | Dipeptidyylipeptidaasi 1:n estäjänä toimiva nitriilijohdannainen ja sen käyttö | |
| RU2009115963A (ru) | Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами | |
| JP2019104748A5 (https=) | ||
| JP2004516314A5 (https=) | ||
| HRP20140950T1 (hr) | Novi spojevi i pripravci, te postupci njihove primjene | |
| JP2019513778A5 (https=) | ||
| JP2011519854A5 (https=) | ||
| RU2007123235A (ru) | Противоопухолевые соединения | |
| JP2010504347A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| RU2006116628A (ru) | Новые производные имидазола и их применение в качестве фармацевтических агентов | |
| JP2011509309A5 (https=) | ||
| JP2005526836A5 (https=) | ||
| JP2022119852A5 (https=) | ||
| JP2022533939A5 (https=) | ||
| JP2010520276A5 (https=) | ||
| NO20063330L (no) | Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer | |
| JP2018527324A5 (https=) | ||
| JP2008517897A5 (https=) | ||
| RU2007147597A (ru) | Производные эрголина и их применение в качестве лигандов хемокинного рецептора | |
| JP2006523626A5 (https=) | ||
| JP2013537193A5 (https=) |